Ozempic, Wegovy: Why GLP-1 Drugs Don't Work for Everyone

New research suggests about 10% of people may carry genetic variants linked to partial GLP-1 resistance, helping explain why drugs like Ozempic and Wegovy do not work equally well for everyone. The article emphasizes that genetics explains only part of treatment response and that routine pharmacogenomic screening is not yet ready for widespread use. It also highlights alternatives for incomplete responders, including bariatric surgery, combination pharmacotherapy, and diet/exercise interventions, but does not indicate an immediate market-moving catalyst.

Analysis

The investable implication is not that GLP-1 demand is weakening, but that the market is underpricing heterogeneity in response. That creates a second-order opportunity for companies with broader obesity pipelines, because the next leg of growth likely comes from patients who either plateau, discontinue, or never start on GLP-1s and need adjunctive therapy rather than a single-agent solution. In other words, this is less a secular peak-growth call on incretins than a mix-shift toward combination regimens, surgery, and outcomes-driven care models.

The near-term loser set is narrower than headlines suggest. Pure-play obesity beneficiaries that depend on a smooth, one-drug adoption curve face greater churn risk if payers begin pushing step-therapy, adherence hurdles, or pharmacogenomic screening before reimbursement. That would slow gross-to-net expansion and extend sales cycles by quarters, while benefiting channel players that can route patients into multidisciplinary care, surgery, nutrition, and chronic-disease management.

The contrarian read is that the real upside is in better patient selection, not a falloff in category demand. If only a minority are true biologic non-responders, the bigger commercial risk is wasted spend on early discontinuers and undifferentiated marketing. Over 6-18 months, the key catalyst is whether payers and large health systems start treating obesity like oncology: stratify, sequence, and combine therapies, which would reward platforms with data, diagnostics, and bundled treatment capability.

From a portfolio perspective, the most attractive trade is to lean into diversified incumbents and away from single-mechanism enthusiasm. The asymmetry is that a precision-medicine turn could compress valuation multiples for “one-shot” obesity stories faster than it slows absolute demand, while names with surgery, nutrition, or multi-pathway assets can capture the same patient flow with lower execution risk.

Key Decisions for Investors

• Long NVO / short a basket of higher-beta obesity pure plays over 3-6 months; thesis is that heterogeneity and discontinuation risk favor scaled franchises with broader label optionality. Use a 2:1 reward-to-risk structure with the short leg sized smaller, because category demand likely stays intact.
• Add calls on HCA and THC over 6-12 months; if combination pharmacotherapy underdelivers, referral volume to bariatric surgery should accelerate, and surgery is the cleanest alternative pathway with durable utilization upside.
• Buy LLY on weakness only if the market overreacts to the article; the better setup is a longer-dated bull call spread, since the main risk is not demand destruction but slower net patient starts and more payer scrutiny, which is manageable for a category leader.
• Initiate a relative-value long lab/diagnostics exposure versus a short in single-product obesity hype names if pharmacogenomic testing starts to enter payer conversations; the catalyst window is 6-18 months, not days.
• Monitor managed-care names for pricing and utilization risk; a long UNH / short obesity-exposed small-cap basket can work if payers impose step edits and prior auth that reduce wasted GLP-1 spend while preserving overall obesity-treatment economics.